Samsung Bioepis Pushes Stelara Rival Into Phase I

Proposed Ustekinumab Biosimilar Is Competing With Several Other Candidates

 
• By Dave Wallace

Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.

Phase One 1 Blocks
Samsung Bioepis’ SB17 ustekinumab biosimilar has started Phase I trials • Source: Shutterstock

More from Biosimilars

More from Products